FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 327:453-457 August 13, 1992 Number 7 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. Although inactivated hepatitis A vaccine is known to be well tolerated and immunogenic in healthy children and adults, its efficacy has yet to be established. METHODS. To evaluate the efficacy of the hepatitis A vaccine in protecting against clinically apparent disease, we conducted a double-blind, placebo-controlled trial in an Hasidic Jewish community in upstate New York that has had recurrent outbreaks of hepatitis A. At the beginning of a summer outbreak, 1037 healthy seronegative children 2 to 16 years of age were randomly assigned to receive one intramuscular injection of a highly purified, formalin-inactivated hepatitis A vaccine or placebo. A case was defined by the presence of typical signs and symptoms, a diagnostic increase in IgM antibody to hepatitis A, and a serum concentration of alanine aminotransferase at least twice the upper limit of normal. Cases occurring greater than or equal to 50 days after the injection were included in the evaluation of efficacy. The children were followed for a mean of 103 days. RESULTS. A total of 519 children received vaccine, and 518 received placebo. The vaccine was well tolerated, with no serious adverse reactions. From day 50 after the injection, 25 cases of clinically apparent hepatitis A occurred in the placebo group and none in the vaccine group (P less than 0.001), confirming that the vaccine had 100 percent protective efficacy. Before day 21, seven cases occurred in the vaccine group and three cases in the placebo group. After that time, there were no cases among vaccine recipients and 34 cases among placebo recipients. CONCLUSIONS. The inactivated purified hepatitis A vaccine that we tested is well tolerated, and a single dose is highly protective against clinically apparent hepatitis A.

Source Information

Kiryas Joel Institute of Medicine, Monroe, N.Y. 10950.

This article has been cited by other articles:

• Victor, J. C., Monto, A. S., Surdina, T. Y., Suleimenova, S. Z., Vaughan, G., Nainan, O. V., Favorov, M. O., Margolis, H. S., Bell, B. P. (2007). Hepatitis A Vaccine versus Immune Globulin for Postexposure Prophylaxis. NEJM 357: 1685-1694 [Abstract] [Full Text]  
• Committee on Infectious Diseases, (2007). Hepatitis A Vaccine Recommendations. Pediatrics 120: 189-199 [Abstract] [Full Text]  
• Wasley, A., Fiore, A., Bell, B. P. (2006). Hepatitis A in the Era of Vaccination. Epidemiol Rev 28: 101-111 [Abstract] [Full Text]  
• Victor, J. C., Surdina, T. Y., Suleimenova, S. Z., Favorov, M. O., Bell, B. P., Monto, A. S. (2006). Person-to-Person Transmission of Hepatitis A Virus in an Urban Area of Intermediate Endemicity: Implications for Vaccination Strategies. Am J Epidemiol 163: 204-210 [Abstract] [Full Text]  
• SACY, R. G., HADDAD, M., BAASIRI, G., KHORIATI, A., GERBAKA, B. J., ABU-ELYAZEED, R. (2005). HEPATITIS A IN LEBANON: A CHANGING EPIDEMIOLOGICAL PATTERN. Am J Trop Med Hyg 73: 453-456 [Abstract] [Full Text]  
• Dagan, R., Leventhal, A., Anis, E., Slater, P., Ashur, Y., Shouval, D. (2005). Incidence of Hepatitis A in Israel Following Universal Immunization of Toddlers. JAMA 294: 202-210 [Abstract] [Full Text]  
• Van Damme, P., Van Herck, K. (2005). Effect of Hepatitis A Vaccination Programs. JAMA 294: 246-248 [Full Text]  
• Karayiannis, P., Main, J., Thomas, H. C. (2004). Hepatitis vaccines. Br Med Bull 70: 29-49 [Full Text]  
• Craig, A. S., Schaffner, W. (2004). Prevention of Hepatitis A with the Hepatitis A Vaccine. NEJM 350: 476-481 [Full Text]  
• Chan, I S. (2003). Proving non-inferiority or equivalence of two treatments with dichotomous endpoints using exact methods. Stat Methods Med Res 12: 37-58 [Abstract]  
• Fleischmann, E. H., Kruppenbacher, J., Bock, H. L., Weber, M. (2002). Active immunization against hepatitis A in dialysis patients. Nephrol Dial Transplant 17: 1825-1828 [Abstract] [Full Text]  
• (2002). Jaundice in primary school pupils. Postgrad. Med. J. 78: 59-60 [Full Text]  
• Averhoff, F., Shapiro, C. N., Bell, B. P., Hyams, I., Burd, L., Deladisma, A., Simard, E. P., Nalin, D., Kuter, B., Ward, C., Lundberg, M., Smith, N., Margolis, H. S. (2001). Control of Hepatitis A Through Routine Vaccination of Children. JAMA 286: 2968-2973 [Abstract] [Full Text]  
• Dennehy, P. H. (2001). Active Immunization in the United States: Developments over the Past Decade. Clin. Microbiol. Rev. 14: 872-908 [Abstract] [Full Text]  
• Allard, R, Beauchemin, J, Bedard, L, Dion, R, Tremblay, M, Carsley, J (2001). Hepatitis A vaccination during an outbreak among gay men in Montreal, Canada, 1995-1997. J. Epidemiol. Community Health 55: 251-256 [Abstract] [Full Text]  
• ASHKENAZI, M., CHODIK, G., LITTNER, M., ALONI, H., LERMAN, Y. (2001). The presence of hepatitis A antibodies in dental workers: A seroepidemiologic study. Journal of the American Dental Association 132: 492-498 [Abstract] [Full Text]  
• Cuthbert, J. A. (2001). Hepatitis A: Old and New. Clin. Microbiol. Rev. 14: 38-58 [Abstract] [Full Text]  
• Staes, C. J., Schlenker, T. L., Risk, I., Cannon, K. G., Harris, H., Pavia, A. T., Shapiro, C. N., Bell, B. P. (2000). Sources of Infection Among Persons With Acute Hepatitis A and No Identified Risk Factors During a Sustained Community-Wide Outbreak. Pediatrics 106: 54e-54 [Abstract] [Full Text]  
• Jacobs, R. J., Margolis, H. S., Coleman, P. J. (2000). The Cost-effectiveness of Adolescent Hepatitis A Vaccination in States With the Highest Disease Rates. Arch Pediatr Adolesc Med 154: 763-770 [Abstract] [Full Text]  
• Gilbert, P. B (2000). Some statistical issues in the design of HIV-1 vaccine and treatment trials. Stat Methods Med Res 9: 207-229 [Abstract]  
• Thompson, P., Lu, J., Kaplan, G. G. (1998). The Cys-Rich Region of Hepatitis A Virus Cellular Receptor 1 Is Required for Binding of Hepatitis A Virus and Protective Monoclonal Antibody 190/4. J. Virol. 72: 3751-3761 [Abstract] [Full Text]  
• Werzberger, A., Kuter, B., Nalin, D. (1998). Six Years' Follow-Up after Hepatitis A Vaccination. NEJM 338: 1160-1160 [Full Text]  
• Zhang, Y., Kaplan, G. G. (1998). Characterization of Replication-Competent Hepatitis A Virus Constructs Containing Insertions at the N Terminus of the Polyprotein. J. Virol. 72: 349-357 [Abstract] [Full Text]  
• Lemon, S. M. (1997). Type A viral hepatitis: epidemiology, diagnosis, and prevention. Clin. Chem. 43: 1494-1499 [Abstract] [Full Text]  
• Lemon, S. M., Thomas, D. L. (1997). Vaccines to Prevent Viral Hepatitis. NEJM 336: 196-204 [Full Text]  
• McMahon, B. J., Beller, M., Williams, J., Schloss, M., Tanttila, H., Bulkow, L. (1996). A Program to Control an Outbreak of Hepatitis A in Alaska by Using an Inactivated Hepatitis A Vaccine. Arch Pediatr Adolesc Med 150: 733-739 [Abstract]  
• Steffen, R., Kane, M. A., Shapiro, C. N., Billo, N., Schoellhorn, K. J., van Damme, P. (1994). Epidemiology and Prevention of Hepatitis A in Travelers. JAMA 272: 885-889 [Abstract]  
• Innis, B. L., Snitbhan, R., Kunasol, P., Laorakpongse, T., Poopatanakool, W., Kozik, C. A., Suntayakorn, S., Suknuntapong, T., Safary, A., Tang, D. B., Boslego, J. W. (1994). Protection Against Hepatitis A by an Inactivated Vaccine. JAMA 271: 1328-1334 [Abstract]  
• Lemon, S. M. (1994). Inactivated Hepatitis A Vaccines. JAMA 271: 1363-1364 [Abstract]  
• Bryan, J. P., Nelson, M. (1994). Testing for Antibody to Hepatitis A to Decrease the Cost of Hepatitis A Prophylaxis With Immune Globulin or Hepatitis A Vaccines. Arch Intern Med 154: 663-668 [Abstract]  
• (1994). Prevention and control of hepatitis A. DTB 32: 9-11 [Abstract] [Full Text]  
• Gardner, P., Schaffner, W. (1993). Immunization of Adults. NEJM 328: 1252-1258 [Full Text]